KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Other Gross PP&E Adjustments: 2010-2024

Historic Other Gross PP&E Adjustments for Regeneron Pharmaceuticals (REGN) over the last 1 years, with Dec 2024 value amounting to $6.3 billion.

  • Regeneron Pharmaceuticals' Other Gross PP&E Adjustments rose 14.06% to $6.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $16.6 billion, marking a year-over-year increase of 14.05%. This contributed to the annual value of $6.3 billion for FY2024, which is 14.06% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Other Gross PP&E Adjustments of $6.3 billion as of Q4 2024, which was up 14.06% from $5.5 billion recorded in Q4 2023.
  • Regeneron Pharmaceuticals' 5-year Other Gross PP&E Adjustments high stood at $6.3 billion for Q4 2024, and its period low was -$15.6 million during Q3 2022.
  • For the 3-year period, Regeneron Pharmaceuticals' Other Gross PP&E Adjustments averaged around $4.2 billion, with its median value being $5.2 billion (2022).
  • Data for Regeneron Pharmaceuticals' Other Gross PP&E Adjustments shows a peak YoY grew of 17.58% (in 2020) over the last 5 years.
  • Regeneron Pharmaceuticals' Other Gross PP&E Adjustments (Quarterly) stood at $3.7 billion in 2020, then grew by 14.62% to $4.2 billion in 2021, then grew by 13.25% to $4.8 billion in 2022, then grew by 14.71% to $5.5 billion in 2023, then increased by 14.06% to $6.3 billion in 2024.
  • Its Other Gross PP&E Adjustments stands at $6.3 billion for Q4 2024, versus $5.5 billion for Q4 2023 and $4.8 billion for Q4 2022.